NCT06729658View on ClinicalTrials.gov

Dopamine and Brain Computer Interface

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 1, 2017

Primary Completion Date

February 27, 2023

Study Completion Date

August 6, 2024

Conditions
Healthy Participants
Interventions
DRUG

Madopar

Experimental group participants will receive Madopar 125mg for 6 days.

DRUG

Placebo

Control group participants will receive placebo for 6 days.

Trial Locations (1)

04103

Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig

All Listed Sponsors
lead

Max Planck Institute for Human Cognitive and Brain Sciences

OTHER

NCT06729658 - Dopamine and Brain Computer Interface | Biotech Hunter | Biotech Hunter